CASI Pharmaceuticals wins Nasdaq extension to meet listing rules
Source: SeekingAlpha
2025-12-23 16:12:21 ET
More on CASI Pharmaceuticals
- CASI Pharmaceuticals appeals NASDAQ delisting determination
- Seeking Alpha’s Quant Rating on CASI Pharmaceuticals
- Historical earnings data for CASI Pharmaceuticals
- Financial information for CASI Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
CASI Pharmaceuticals wins Nasdaq extension to meet listing rules
CASI Pharmaceuticals Inc.
NASDAQ: CASI
CASI Trading
-51.71% G/L:
$0.3701 Last:
2,892,826 Volume:
$0.34 Open:
CASI Latest News
February 25, 2026 09:00:00 am
CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
January 15, 2026 09:00:00 am
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
January 12, 2026 09:00:00 am
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
December 23, 2025 04:05:00 pm
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
CASI Stock Data
$13,207,511
8,691,394
14.4%
7
N/A
Biotechnology & Life Sciences
Healthcare
US
Beijing
